Lv2
130 积分 2025-05-29 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
19天前
已完结
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy
25天前
已完结
Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis
1个月前
已完结
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
2个月前
已完结
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial
2个月前
已完结
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
2个月前
已完结
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
2个月前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
3个月前
已完结
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update
3个月前
已完结
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial
4个月前
已完结
皖公网安备34019202002308
